ALXO · Alx Oncology Holdings Inc
Market Cap
$276.55M
Shares
138.28M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jason Lettmann | Chief Executive Officer | $2,470,844 |
| Harish Shantharam | Chief Financial Officer | $1,700,673 |
| Jaume Pons | Former President and Chief Scientific Officer | $973,729 |
| Shelly Wong | Senior Vice President, Finance and Chief Accounting Officer | $940,405 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jason Lettmann | Chief Executive Officer | $6,640,830 |
| Sophia Randolph | M.D., Ph.D. Former Chief Medical Officer | $3,530,138 |
| Jaume Pons | Former President and Chief Scientific Officer | $3,017,955 |
| Peter Garcia | Former Chief Financial Officer | $2,697,079 |
| Shelly Wong | Senior Vice President, Finance and Chief Accounting Officer | $1,505,161 |
| Shelly Pinto | Senior Vice President, Finance and Chief Accounting Officer | $1,505,161 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jason Lettmann | Chief Executive Officer | $4,857,183 |
| Jaume Pons | Former President and Chief Scientific Officer | $2,745,326 |
| Sophia Randolph | M.D., Ph.D. Former Chief Medical Officer | $1,374,892 |
| Peter Garcia | Former Chief Financial Officer | $1,302,946 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jaume Pons | President, Chief Scientific Officer and former Chief Executive Officer | $3,734,316 |
| Sophia Randolph | M.D., Ph.D. Chief Medical Officer | $2,084,570 |
| Peter Garcia | Chief Financial Officer | $1,753,821 |
| Jason Lettmann | Chief Executive Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jaume Pons | Chief Executive Officer and President | $10,112,978 |
| Shelly Pinto | Vice President, Finance and Chief Accounting Officer | $7,116,319 |
| Sophia Randolph | M.D., Ph.D. Chief Medical Officer | $4,751,470 |
| Peter Garcia | Chief Financial Officer | $4,751,470 |
| Steffen Pietzke | Former Vice President, | $104,813 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jaume Pons | Chief Executive Officer and President | $7,234,431 |
| Peter Garcia | Chief Financial Officer | $2,824,447 |
| Sophia Randolph | M.D., Ph.D. Chief Medical Officer | $2,757,365 |
| Steffen Pietzke | Former Vice President, | $1,562,865 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jaume Pons | Chief Executive Officer and President | $704,202 |
| Sophia Randolph | M.D., Ph.D. Chief Medical Officer | $497,334 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael Listgarten | General Counsel | Appointed | 2026-06-30 |
| Jeff Knight | Chief Development and Operating Officer | Appointed | 2026-04-13 |
| Barbara Klencke, M.D. | consulting interim Chief Medical Officer | Appointed | 2025-09-12 |
| Alan Sandler, M.D. | Chief Medical Officer | Resigned | 2025-09-12 |
| Alan Sandler, M.D. | Class II director | Appointed | 2025-09-12 |
| Barbara Klencke, M.D. | member of the Board of Directors | Resigned | 2025-09-12 |
| Daniel Curran, M.D. | Class III director | Appointed | 2025-08-12 |
| Chris Takimoto | Class III director | Appointed | 2025-01-22 |
| Barbara Klencke | Class II director | Appointed | 2025-01-22 |
| Shelly Pinto | Interim Chief Financial Officer | Resigned | 2025-01-22 |
| Harish Shantharam | Chief Financial Officer | Appointed | 2025-01-22 |
| Alan Sandler | member of the Board | Resigned | 2024-11-14 |
| Peter Garcia | Chief Financial Officer | Resigned | 2024-11-14 |
| Alan Sandler | Chief Medical Officer | Appointed | 2024-11-14 |
| Peter Garcia | Chief Financial Officer | Resigned | 2024-11-07 |
| Sophia Randolph, M.D., Ph.D. | Chief Medical Officer | Resigned | 2024-10-04 |
| Sophia Randolph, M.D., Ph.D. | members of the Company's Board | Resigned | 2024-08-06 |
| Jaume Pons, Ph.D. | members of the Company's Board | Resigned | 2024-08-06 |
| Alan Sandler, M.D. | Class III director of the Board of Directors | Appointed | 2024-08-06 |
| Itziar Canamasas, Ph.D. | member of the Board | Resigned | 2024-05-02 |
| Jack Nielsen | member of the Company's Board of Directors | Resigned | 2024-05-02 |
| Jaume Pons | Chief Scientific Officer | Appointed | 2023-09-06 |
| Jason Lettmann | Chief Executive Officer | Appointed | 2023-09-06 |
| Scott Garland | Class III director | Appointed | 2022-11-29 |
| Dr. Itziar Canamasas | Board of Directors | Appointed | 2022-04-12 |
Key facts
CIK
1810182
CUSIP
00166B105
13F (30d)
87 filings
87 filers
Visit website
Investor relations